MARKET

VTGN

VTGN

VistaGen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.800
+0.010
+0.36%
After Hours: 2.800 0 0.00% 16:00 09/22 EDT
OPEN
2.820
PREV CLOSE
2.790
HIGH
2.840
LOW
2.770
VOLUME
716.59K
TURNOVER
--
52 WEEK HIGH
3.550
52 WEEK LOW
0.5551
MARKET CAP
540.13M
P/E (TTM)
-7.5512
1D
5D
1M
3M
1Y
5Y
We're Interested To See How VistaGen Therapeutics (NASDAQ:VTGN) Uses Its Cash Hoard To Grow
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, VistaGen...
Simply Wall St. · 2d ago
BRIEF-VistaGen Therapeutics Advances Phase 3 Program For PH94B In Social Anxiety Disorder
reuters.com · 09/13 11:00
VistaGen Therapeutics Further Advances PALISADE Phase 3 Program for PH94B in Social Anxiety Disorder with Initiation of PALISADE-2
PALISADE Phase 3 Program focused on PH94B’s potential as a rapid-onset, acute treatment of anxiety in adults with social anxiety disorderSOUTH SAN FRANCISCO, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharma...
GlobeNewswire · 09/13 10:00
VistaGen Therapeutics Starts Phase 3 Study of Social Anxiety Disorder Drug
MT Newswires · 09/13 06:53
Orbimed Advisors Llc Buys SPDR Biotech ETF, NeuroPace Inc, Janux Therapeutics Inc, Sells ...
GuruFocus News · 09/09 15:38
VistaGen Therapeutics to Participate in Baird's 2021 Global Healthcare Conference
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system ("CNS") disorders...
GlobeNewswire · 09/08 12:00
VistaGen Therapeutics Sponsored Study Titled 'Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)' Posted To ClinicalTrials.Gov; Study Not Yet Recruiting
https://clinicaltrials.gov/ct2/show/NCT05030350
Benzinga · 09/01 14:11
VistaGen Therapeutics-Sponsored Study Titled 'PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2 (Palisade-2)' Posted To ClinicalTrials.Gov Website; Study Not Yet Recruiting
https://clinicaltrials.gov/ct2/show/NCT05011396
Benzinga · 08/18 13:40
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VTGN. Analyze the recent business situations of VistaGen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VTGN stock price target is 7.00 with a high estimate of 9.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 108
Institutional Holdings: 123.72M
% Owned: 64.14%
Shares Outstanding: 192.90M
TypeInstitutionsShares
Increased
23
24.56M
New
46
8.03M
Decreased
22
10.05M
Sold Out
19
4.98M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.30%
Pharmaceuticals & Medical Research
-0.11%
Key Executives
Non-Executive Chairman/Independent Director
Jon Saxe
President/Founder/Chief Scientific Officer
H. Ralph Snodgrass
Chief Executive Officer/Director
Shawn Singh
Chief Financial Officer/Vice President/Secretary
Jerrold Dotson
Senior Vice President
Mark Ginski
Other/Director
Ann Cunningham
Other
Mark Smith
Independent Director
Joanne Curley
Independent Director
Margaret Fitzpatrick
Independent Director
Jerry Gin
Independent Director
Mary Rotunno
No Data
About VTGN
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). The company's pipeline includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that is preparing for Phase III clinical trial for social anxiety disorder (SAD), PH10, a neuroactive nasal spray that is planning for Phase 2b development as a stand-alone treatment for depressive disorder (MDD), and AV-101 which the Company is developing for the treatment of depressive disorder (MDD), suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy. In addition, the Company has developed a human pluripotent stem cell (hPSC) technology platform, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs).

Webull offers kinds of Vistagen Therapeutics Inc stock information, including NASDAQ:VTGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VTGN stock methods without spending real money on the virtual paper trading platform.